This report implies that HDAC inhibitory therapy will not have a protective effect, although the possible use of HDAC inhibitors as a therapy for renal fibrosis was established in UUO [151,153,154], streptozotocin-induced diabetic nephropathy [155-157], other ischemia models [158,159], and adriamycin nephropathy [106]. The gene discussed is HDAC9; the disease is diabetic kidney disease.